

# Orthofix Schedules Second Quarter Earnings Release and Conference Call for August 8, 2023, and Announces Participation in Upcoming Investor Conference

7/25/2023

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023 after market close. The Company will host a conference call and webcast to review results at 4:30 p.m. ET the same day.

Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations, and entering the event passcode 9556380. A webcast of the conference call and a copy of the release may be accessed at [ir.Orthofix.com](https://ir.Orthofix.com).

Additionally, the Company today announced that it will participate at the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston, MA. Management is scheduled to present on Thursday, August 10, 2023, at 10:30 a.m. ET. Interested parties can access a live webcast of the presentation on the Investors section of the Orthofix website at [ir.Orthofix.com](https://ir.Orthofix.com). An archived recording of the event will be available for 90 days.

## About Orthofix:

On January 5, 2023, Orthofix and SeaSpine merged to form a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in approximately 68 countries worldwide

The Company is headquartered in Lewisville, Texas and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product

innovation, production, and medical education for orthopedics. The combined Company's global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France and Sao Paulo, Brazil. A new name for the combined entity will be announced at a future date; the Company will continue to operate as Orthofix until said announcement.

## **Investor Relations**

Louisa Smith, Gilmartin Group

**[ir@orthofix.com](mailto:ir@orthofix.com)**

Source: Orthofix Medical Inc.